Appia Bio, an early-stage biotechnology company located in Los Angeles, California, was founded in 2020. The company's core focus is on creating and developing engineered allogeneic cell therapies that target a wide range of medical indications through its innovative and scalable platform, ACUA (Appia Cells Utilized for Allogeneic).
The ACUA technology platform is foundational to Appia Bio's mission, utilizing advancements in lymphocyte biology and integrating cutting-edge techniques in CAR (chimeric antigen receptor) and TCR (T-cell receptor) gene engineering. This approach enables the production of CAR-iNKT (CAR-engineered invariant natural killer T) cell subtypes from hematopoietic stem cells, promising broader patient access to therapies.
In its recent funding activity, Appia Bio secured a $52.00M Series A investment on 01 May 2021, led by notable investors such as Two Sigma Ventures, 8VC, Freeflow Ventures, and Sherpa Venture Partners. This significant investment underscores strong investor confidence in the company’s potential in revolutionizing cell therapies.
Wugen